APLF (Aprataxin and PNK-like Factor) is a multifunctional DNA repair protein involved in the base excision repair (BER) pathway, critical for maintaining genomic stability. It interacts with key repair proteins, such as XRCC4 and XRCC1. to facilitate DNA single-strand break repair and resolve abortive DNA ligation intermediates. APLF contains three conserved domains: an N-terminal forkhead-associated (FHA) domain for protein-protein interactions, a central zinc finger domain, and a C-terminal poly(ADP-ribose) (PAR)-binding zinc finger (PBZ) domain, enabling its recruitment to DNA damage sites via PAR chains synthesized by PAR polymerases (PARPs).
APLF antibodies are essential tools for studying its role in DNA damage response, replication stress, and genome integrity. They are used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect APLF expression, localization, and interactions in cellular models. Research has linked APLF dysfunction to neurodegenerative disorders, such as ataxia-oculomotor apraxia syndrome (AOA), and cancer, where impaired DNA repair contributes to disease progression. Antibodies targeting specific domains (e.g., PBZ) help dissect mechanistic contributions of APLF to PAR-dependent repair processes. Commercial APLF antibodies are typically raised in rabbits or mice, validated for specificity across human and model organisms. Ongoing studies leverage these reagents to explore APLF's potential as a therapeutic target or biomarker in diseases associated with defective DNA repair.